ClinicalTrials.gg
Not yet recruitingNCT07854145Updated Oct 30, 2026

Starry-Sky Projection and Maternal Voice for Sleep After Pediatric Cardiac Surgery

An interventional study of Starry-Sky Projection and Conventional Lighting in Congenital Heart Disease (CHD) and Postoperative Sleep, sponsored by Shanghai Jiao Tong University School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Shanghai Jiao Tong University School of Medicine · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 30, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
6 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Heart Defects, Congenital with a site in China — 27 open to participants now, 30 under way, none of them phase 3. Heart Defects, Congenital · China.

Planned enrollment
20th of 41
172 · median 160
Started
2026
with 7 others
No phase
31 of 79
12 open now
Primary completion
2027-03
later than 17 of 29 live
Registered
79th of 79
by date
Lead sponsor
4 of 79
Shanghai Jiao Tong University School of Medicine

Among the 79 studies in Heart Defects, Congenital with a site in China, this one is the 20th largest by planned enrollment of the 41 interventional ones that give a count, is one of 8 that started in 2026, is one of 31 with no phase, reaches primary completion later than 17 of the 29 other live ones, and was the 79th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

27 of the 79 studies in Heart Defects, Congenital with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 6 Months to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Heart Defects, Congenital with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether a starry-sky projection affects sleep during the early period after cardiac surgery in young children. The main question it aims to answer is:

  • Does a starry-sky projection improve how well children sleep during the first three nights after surgery compared with routine nighttime lighting? The study will also explore whether sleep outcomes differ between children who listen to their mother's recorded voice and those who listen to an unfamiliar woman's recorded voice, and whether the effect of the starry-sky projection differs depending on the type of voice.

Children aged 6 months to 6 years will be randomly assigned to one of four combinations of visual and sound conditions. They will:

  • Receive either a starry-sky projection or routine nighttime lighting
  • Listen to either their mother's recorded voice or an unfamiliar woman's recorded voice
  • Have their sleep monitored during the first three nights after surgery using a contactless device placed under the pillow that does not require sensors attached to the child.
03

Conditions studied

  • Congenital Heart Disease (CHD)
  • Postoperative Sleep
04

Who can participate

Ages eligible
6 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A confirmed diagnosis of congenital heart disease.
  • Age between 6 months and 6 years.
  • Scheduled to undergo their first elective open-heart surgery.
  • An anticipated postoperative stay in the cardiac intensive care unit (CICU) of at least 48 hours.
  • Written provided by a parent or legal guardian.

Exclusion criteria

Exclusion Criteria:

  • Epilepsy or another severe neurological disorder.
  • A severe psychiatric disorder.
  • Hearing impairment that interferes with the perception of auditory stimuli.
  • Visual impairment that interferes with the perception of visual stimuli.
  • Malformations of other organs or pre-existing severe comorbidities.
  • A history of chronic pain.
  • A previously diagnosed sleep disorder.
  • Endotracheal tube could not be successfully removed before 7 p.m. on the day of surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
172 participants (estimated)

Study arms

  • Experimental
    Starry-Sky Projection + Maternal Voice

    Behavioral: Starry-Sky Projection · Behavioral: Maternal Voice

  • Experimental
    Starry-Sky Projection + Unfamiliar Female Voice

    Behavioral: Starry-Sky Projection · Behavioral: Unfamiliar Female Voice

  • Active comparator
    Conventional Lighting + Maternal Voice

    Other: Conventional Lighting · Behavioral: Maternal Voice

  • Active comparator
    Conventional Lighting + Unfamiliar Female Voice

    Other: Conventional Lighting · Behavioral: Unfamiliar Female Voice

Interventions

  • BehavioralStarry-Sky Projection

    A starry-sky projector will display gently moving, diffuse star-like points on the ceiling, avoiding direct light exposure to the child's eyes. Settings will remain constant, without rapid movement, frequent colour changes, or visible flicker. Built-in audio will be disabled. Sessions will last 30 minutes before anticipated sleep onset on postoperative nights 0-2.

  • OtherConventional Lighting

    Participants will remain under routine nocturnal lighting in the CICU or general ward without additional projection.

  • BehavioralMaternal Voice

    A personalised recording from the child's mother containing the child's name, reassuring and sleep-related phrases, and a familiar lullaby or gentle melody will be played for 30 minutes before anticipated sleep onset. The recording will be played using a speaker positioned approximately 20 cm from the child's ear, with sound intensity maintained at 45-50 dB.

  • BehavioralUnfamiliar Female Voice

    A standardized recording by an unfamiliar adult woman who is not involved in the child's clinical care will be played for 30 minutes before anticipated sleep onset. The recording will contain generic reassuring and sleep-related phrases and a gentle lullaby or nursery rhyme. Playback duration, speaker placement, and sound intensity will be identical to the maternal voice condition.

06

What researchers measure

Primary outcomes

  1. Sleep Efficiency

    Sleep efficiency is defined as the percentage of total sleep time (TST) relative to time in bed (TIB) during the sleep-related nocturnal interval. TIB refers to the interval from the start of an attempt to sleep until the end of the nocturnal sleep opportunity and includes sleep onset latency and intervening wakefulness. Sleep efficiency will be assessed using a contactless ballistocardiography (BCG)-based sleep monitoring mat during postoperative nights 0-2. The mean sleep efficiency across the three postoperative nights will be used as the primary outcome measure. Higher values indicate better sleep efficiency.

    Time frame: Postoperative nights 0, 1, and 2

Secondary outcomes

  1. Total Sleep Time

    Total sleep time during the nocturnal monitoring period, measured using a contactless sleep monitoring mat.

    Time frame: Postoperative nights 0, 1, and 2

  2. Sleep-Onset Latency

    Time from the beginning of the nocturnal sleep monitoring period to sleep onset, measured using a contactless sleep monitoring mat.

    Time frame: Postoperative nights 0, 1, and 2

  3. Wake After Sleep Onset

    Total duration of wakefulness occurring after sleep onset during the nocturnal monitoring period, measured using a contactless sleep monitoring mat.

    Time frame: Postoperative nights 0, 1, and 2

  4. Sleep Fragmentation Index

    Sleep fragmentation index derived from the contactless sleep monitoring mat, reflecting the degree of sleep disruption during the nocturnal monitoring period.

    Time frame: Postoperative nights 0, 1, and 2

  5. Sleep-Stage Distribution

    Estimated distribution of sleep stages during the nocturnal monitoring period, expressed as the proportion of total sleep time and measured using a contactless sleep monitoring mat.

    Time frame: Postoperative nights 0, 1, and 2

  6. Incidence of Postoperative Delirium

    Postoperative delirium will be assessed using the Cornell Assessment of Pediatric Delirium (CAPD). A total CAPD score ≥9 will indicate a positive delirium screen. Assessments will be performed every 12 hours.

    Time frame: Postoperative night 0 through postoperative day 2

  7. Richmond Agitation-Sedation Scale Score

    Sedation and agitation will be assessed using the Richmond Agitation-Sedation Scale (RASS). Scores range from -5 to +4, with lower scores indicating deeper sedation and higher scores indicating greater agitation. Assessments will be performed every 4 hours.

    Time frame: Postoperative night 0 through postoperative day 2

  8. Pain Score

    Postoperative pain will be assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale. Scores range from 0 to 10, with higher scores indicating greater pain severity. Assessments will be performed every 4 hours.

    Time frame: Postoperative night 0 through postoperative day 2

  9. Postoperative Sedative Exposure

    Administration of dexmedetomidine and other sedative medications will be recorded to characterize postoperative sedative exposure.

    Time frame: Postoperative day 0 through postoperative day 2

  10. Postoperative Analgesic Exposure

    Administration of sufentanil and other analgesic medications will be recorded to characterize postoperative analgesic exposure.

    Time frame: Postoperative day 0 through postoperative day 2

  11. Postoperative Vasoactive Medication Exposure

    Administration of dopamine and other vasoactive medications will be recorded to characterize postoperative vasoactive medication exposure.

    Time frame: Postoperative day 0 through postoperative day 2

  12. Heart Rate Variability

    Heart rate variability will be continuously measured using the 5S Sleep Tracking Mat as an objective indicator of autonomic regulation.

    Time frame: Postoperative nights 0, 1, and 2

  13. CICU Length of Stay

    Cardiac intensive care unit (CICU) length of stay will be calculated from postoperative CICU admission to CICU discharge.

    Time frame: Measured in days admitted to the CICU, an average of 2 days

  14. Total Hospital Length of Stay

    Total hospital length of stay will be calculated as the number of days from hospital admission to hospital discharge.

    Time frame: Measured in days admitted to the hospital, an average of 10 days.

  15. Parental satisfaction

    Parental satisfaction with the child's overall hospital care will be assessed using a 100-mm visual analogue scale (VAS), ranging from 0 mm ("very dissatisfied") to 100 mm ("very satisfied"). Higher scores indicate greater satisfaction.

    Time frame: On the day of discharge, an average of 10 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 4 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Oct 2026 → Nov 2026, primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 2, 2026
StartEst.
Nov 1, 2026was Oct 2026
Primary completionEst.
Mar 31, 2027was Dec 2026
CompletionEst.
Mar 31, 2027was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 8, 2026→Nov 1, 2026
Oct 30, 2026
Primary completion
Dec 31, 2026→Mar 31, 2027
Oct 30, 2026
Study completion
Dec 31, 2026→Mar 31, 2027
Oct 30, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 30, 2026
    Start date Oct 8, 2026→Nov 1, 2026
    Primary completion Dec 31, 2026→Mar 31, 2027
    Study completion Dec 31, 2026→Mar 31, 2027
    + 2 other changes: verification date and arm descriptions
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854145
Responsible party
Biyu Shen (Chief Nurse, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
Oct 2, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Biyu Shen, PhD
Contact
shenbiyu@126.com
+86 13862937317

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion